This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rao, C. V. Articles by Reddy, B. S. Search for Related Content PubMed PubMed Citation Articles by Rao, C. V. Articles by Reddy, B. S.

Chemopreventive Effect of Oltipraz during Different Stages of Experimental Colon Carcinogenesis Induced by Azoxymethane in Male F344 Rats¹

Division of Nutritional Carcinogenesis [C. V. R., M. K., B. S. R.] and Division of Pathology [A. R.], American Health Foundation, Valhalla, New York 10595, and Division of Cancer Control and Prevention, Chemoprevention Branch, National Cancer Institute Bethesda, Maryland 20892 [G. J. K.]

Oltipraz [5-(2-pyrazinyl)-4-methyl-1,2-dithiole-3-thione], a substituted 1,2-dithiole-3-thione, protects against the acute and chronic toxicities of many xenobiotics and prevents chemically induced carcinogenicity in several target organs of rodents. The effects of dietary oltipraz, fed during the initiation and postinitiation stages, on azoxymethane-induced colon carcinogenesis and on the levels of several detoxifying enzymes, namely, glutathione S-transferase, NAD(P)H:quinone reductase, and UDP-glucurinyl transferase activities, were studied in male F344 rats. At 5 weeks of age, groups of animals were fed the control diet (modified AIN-76A diet) or a diet containing 200 ppm (40% maximum tolerated dose) of oltipraz. At 7 weeks of age, all animals except those in the vehicle (normal saline solution)-treated groups were given two weekly s.c. injections of azoxymethane at a dose of 15 mg/kg body weight. Three days after the second injection of azoxymethane, the groups of animals fed the oltipraz diet were transferred to the control diet (termed the initiation period) and the groups of animals receiving the control diet were transferred to the oltipraz diet (termed the positinitiation period). All groups were continued on this regimen until the termination of the experiment at 52 weeks after the carcinogen treatment. Intestinal tumors were evaluated histopathologically using routine procedures. Liver, colonic mucosa, and tumors were analyzed for glutathione S-transferase, NAD(P)H:quinone reductase, and UDP-glucurinyl transferase activities. The results indicate that oltipraz administered during the initiation stage significantly inhibited the incidence and multiplicity of invasive adenocarcinomas of the colon (P < 0.001), as well as the multiplicity of invasive and noninvasive adenocarcinomas (P < 0.01). Feeding of oltipraz during the postinitiation phase completely suppressed the formation of invasive adenocarcinomas (P < 0.0001) and significantly inhibited the formation of noninvasive and total adenocarcinomas, as well as the multiplicity (tumors/tumor-bearing animal, P < 0.001). Furthermore, oltipraz significantly suppressed the tumor volume when administered during the initiation phase (>80%) or the postinitiation (>93%) phase. Animals fed the oltipraz diet during the positinitiation stage showed increased levels of glutathione S-transferase, NAD(P)H:quinone reductase, and UDP-glucurinyl transferase activities (2–6-fold). Although the precise mechanism by which oltipraz inhibits colon tumor initiation and/or promotion remains to be elucidated, it is likely that the effect during the initiation stage may be due to an alteration of carcinogen metabolism.

¹ Supported by USPHS Grant CA 17613 and Contract CN-85095-01.

² To whom requests for reprints should be addressed, at American Health Foundation, 1 Dana Road, Valhalla, NY 10595.

Received 12/14/92. Accepted 3/24/93.

This article has been cited by other articles:

				M. S. Ko, S. J. Lee, J. W. Kim, J. W. Lim, and S. G. Kim DIFFERENTIAL EFFECTS OF THE OXIDIZED METABOLITES OF OLTIPRAZ ON THE ACTIVATION OF CCAAT/ENHANCER BINDING PROTEIN-{beta} AND NF-E2-RELATED FACTOR-2 FOR GSTA2 GENE INDUCTION Drug Metab. Dispos., August 1, 2006; 34(8): 1353 - 1360. [Abstract] [Full Text] [PDF]

				S. Sharma, P. Gao, and V. E. Steele The chemopreventive efficacy of inhaled oltipraz particulates in the B[a]P-induced A/J mouse lung adenoma model Carcinogenesis, August 1, 2006; 27(8): 1721 - 1727. [Abstract] [Full Text] [PDF]

				S. J. Lee and S. G. Kim Role of p90 Ribosomal S6-Kinase-1 in Oltipraz-Induced Specific Phosphorylation of CCAAT/Enhancer Binding Protein-beta for GSTA2 Gene Transactivation Mol. Pharmacol., January 1, 2006; 69(1): 385 - 396. [Abstract] [Full Text] [PDF]

				E. J. Bae and S. G. Kim Enhanced CCAAT/Enhancer-Binding Protein {beta}-Liver-Enriched Inhibitory Protein Production by Oltipraz, Which Accompanies CUG Repeat-Binding Protein-1 (CUGBP1) RNA-Binding Protein Activation, Leads to Inhibition of Preadipocyte Differentiation Mol. Pharmacol., September 1, 2005; 68(3): 660 - 669. [Abstract] [Full Text] [PDF]

				A. Begleiter, K. Sivananthan, T. J. Curphey, and R. P. Bird Induction of NAD(P)H Quinone: Oxidoreductase1 Inhibits Carcinogen-induced Aberrant Crypt Foci in Colons of Sprague-Dawley Rats Cancer Epidemiol. Biomarkers Prev., June 1, 2003; 12(6): 566 - 572. [Abstract] [Full Text] [PDF]

				T. Kawamori, N. Uchiya, T. Sugimura, and K. Wakabayashi Enhancement of colon carcinogenesis by prostaglandin E2 administration Carcinogenesis, May 1, 2003; 24(5): 985 - 990. [Abstract] [Full Text] [PDF]

				M.-K. Kwak, N. Wakabayashi, K. Itoh, H. Motohashi, M. Yamamoto, and T. W. Kensler Modulation of Gene Expression by Cancer Chemopreventive Dithiolethiones through the Keap1-Nrf2 Pathway. IDENTIFICATION OF NOVEL GENE CLUSTERS FOR CELL SURVIVAL J. Biol. Chem., February 28, 2003; 278(10): 8135 - 8145. [Abstract] [Full Text] [PDF]

				K. W. Kang, I. J. Cho, C. H. Lee, and S. G. Kim Essential Role of Phosphatidylinositol 3-Kinase-Dependent CCAAT/Enhancer Binding Protein {beta} Activation in the Induction of Glutathione S-Transferase by Oltipraz J Natl Cancer Inst, January 1, 2003; 95(1): 53 - 66. [Abstract] [Full Text] [PDF]

				E. Le Ferrec, D. Lagadic-Gossmann, C. Rauch, C. Bardiau, K. Maheo, F. Massiere, M. Le Vee, A. Guillouzo, and F. Morel Transcriptional Induction of CYP1A1 by Oltipraz in Human Caco-2 Cells Is Aryl Hydrocarbon Receptor- and Calcium-dependent J. Biol. Chem., June 28, 2002; 277(27): 24780 - 24787. [Abstract] [Full Text] [PDF]

				P. J. O’Dwyer, C. Szarka, J. M. Brennan, P. B. Laub, and J. M. Gallo Pharmacokinetics of the Chemopreventive Agent Oltipraz and of Its Metabolite M3 in Human Subjects after a Single Oral Dose Clin. Cancer Res., December 1, 2000; 6(12): 4692 - 4696. [Abstract] [Full Text]

				A. B. Benson III, O. I. Olopade, M. J. Ratain, A. Rademaker, S. Mobarhan, L. Stucky-Marshall, S. French, and M. E. Dolan Chronic Daily Low Dose of 4-Methyl-5-(2-pyrazinyl)-1,2-dithiole-3-thione (Oltipraz) in Patients with Previously Resected Colon Polyps and First-Degree Female Relatives of Breast Cancer Patients Clin. Cancer Res., October 1, 2000; 6(10): 3870 - 3877. [Abstract] [Full Text]

				P. A. Janne and R. J. Mayer Chemoprevention of Colorectal Cancer N. Engl. J. Med., June 29, 2000; 342(26): 1960 - 1968. [Full Text] [PDF]

				M LANGMAN and P BOYLE Chemoprevention of colorectal cancer Gut, October 1, 1998; 43(4): 578 - 585. [Abstract] [Full Text] [PDF]